Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Change in Receivables (2016 - 2025)

Iradimed (IRMD) has disclosed Change in Receivables for 13 consecutive years, with $2.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Receivables rose 269.91% to $2.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.4 million, a 239.09% increase, with the full-year FY2024 number at -$1.8 million, down 109.29% from a year prior.
  • Change in Receivables was $2.9 million for Q3 2025 at Iradimed, up from -$1.8 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $2.9 million in Q3 2025 to a low of -$1.8 million in Q2 2025.
  • A 5-year average of $496351.5 and a median of $369255.0 in 2021 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: skyrocketed 15386.55% in 2022, then tumbled 213.03% in 2023.
  • Iradimed's Change in Receivables stood at $897395.0 in 2021, then soared by 197.52% to $2.7 million in 2022, then tumbled by 118.68% to -$498857.0 in 2023, then skyrocketed by 137.85% to $188810.0 in 2024, then soared by 1428.48% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Change in Receivables are $2.9 million (Q3 2025), -$1.8 million (Q2 2025), and $2.1 million (Q1 2025).